These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26392331)

  • 1. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
    Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
    Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen.
    Kellner C; Lutz S; Oberg HH; Wesch D; Otte A; Diemer KJ; Wilcken H; Bauerschlag D; Glüer CC; Wichmann C; Kabelitz D; Leusen JHW; Klausz K; Humpe A; Gramatzki M; Peipp M
    Biol Chem; 2022 Apr; 403(5-6):545-556. PubMed ID: 34717050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
    Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses.
    Klimosch SN; Bartel Y; Wiemann S; Steinle A
    Blood; 2013 Oct; 122(14):2380-9. PubMed ID: 23929856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide mimicry of AICL inhibits cytolysis of NK cells by blocking NKp80-AICL recognition.
    Huang H; Zheng X; Tian Z; Sun R
    Immunol Invest; 2010; 39(6):587-97. PubMed ID: 20653426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
    Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
    Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction.
    Welte S; Kuttruff S; Waldhauer I; Steinle A
    Nat Immunol; 2006 Dec; 7(12):1334-42. PubMed ID: 17057721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.
    Cao G; Wang J; Zheng X; Wei H; Tian Z; Sun R
    J Biol Chem; 2015 Dec; 290(50):29964-73. PubMed ID: 26472927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
    Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
    Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
    Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
    J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
    Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
    J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
    Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
    J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling.
    Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H
    Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.